GUIDED THERAPEUTICS INC

Form 8-K June 19, 2012			
SECURITIES AND EXCH	ANGE COMMI	ISSION	
Washington, D.C. 20549			
FORM 8-K			
CURRENT REPORT			
Pursuant to Section 13 or 15(d) of the		
Securities Exchange Act of 1	934		
Date of Report (Date of Earli	est Event) June 1	9, 2012; (June 19, 2012)	
GUIDED THERAPEUTICS	S, INC.		
(Exact Name of Registrant a	s Specified in Its	Charter)	
Delaware	0-22179	58-2029543	

(State or Other Jurisdiction of (Commission File Number) (IRS Employer Identification No.)

Incorporation)

5835 Peachtree Corners East, Suite D	30092
Norcross, Georgia	
(Address of Principal Executive Offices)	(Zip Code)
Registrant's Telephone Number, Includin	g Area Code: (770) 242-8723
Check the appropriate box below if the Fe the registrant under any of the following	orm 8-K filing is intended to simultaneously satisfy the filing obligation of provisions:
[] Written communications pursuant to	Rule 425 under the Securities Act (17 CFR 230.425)
[] Soliciting material pursuant to Rule 1	4a-12 under the Exchange Act (17 CFR 240.14a-12)
[] Pre-commencement communications	pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[] Pre-commencement communications	pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 7.01 (Regulation)	FD Disclosure)
---------------------------	----------------

On June 19, 2012, the registrant publicly issued a press release announcing the Canadian debut of LuViva® Advanced Cervical Scan and orders for eight demonstration units to support a Canadian product launch, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number Exhibit

99.1 Press Release dated June 19, 2012

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GUIDED THERAPEUTICS, INC.

By: /s/ Mark L. Faupel, Ph.D. Mark L. Faupel, Ph.D. CEO & President

Date: June 19, 2012

3